hydroxyurea has been researched along with Acquired Immunodeficiency Syndrome in 20 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a pilot phase I, open-label, randomized, single-dose, four-way crossover trial to investigate the fasted and non-fasted residual variance of AUC, C(max) and the oral bioavailability of ddI and HU, co-formulated as VS411, and administered as two different fixed-dose combination formulations compared to commercially available ddI (Videx EC) and HU (Hydrea) when given simultaneously." | 2.75 | Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS. ( De Forni, D; Lori, F; Stevens, MR, 2010) |
| " The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies." | 2.40 | Pharmacokinetics and pharmacodynamics of hydroxyurea. ( Gwilt, PR; Tracewell, WG, 1998) |
| " Progress is also highlighted about dosing regimens, antiretroviral resistance, and reconstitution of the immune system." | 1.30 | Moving forward: a treatment overview from the 12th World AIDS Conference. ( Agosto, M, 1998) |
| "Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in blood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS)." | 1.29 | Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. ( Cara, A; Gallo, RC; Lisziewicz, J; Lori, F; Malykh, A; Sun, D; Weinstein, JN, 1994) |
| "Paul, Director of the Office of AIDS Research (OAR) at the U." | 1.29 | Basic science and clinical trials: interview with William Paul, director of the Office of AIDS Research. Interview by John S James. ( Paul, W, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (70.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Forni, D | 1 |
| Stevens, MR | 1 |
| Lori, F | 4 |
| Uglietti, A | 1 |
| Maserati, R | 2 |
| Gandhi, R | 1 |
| Flexner, C | 1 |
| de Mendoza, C | 1 |
| Paxinos, E | 1 |
| Barreiro, P | 1 |
| Camino, N | 1 |
| Núñez, M | 1 |
| Soriano, V | 1 |
| Reisler, RB | 1 |
| Murphy, RL | 1 |
| Redfield, RR | 1 |
| Parker, RA | 1 |
| Malykh, A | 1 |
| Cara, A | 1 |
| Sun, D | 1 |
| Weinstein, JN | 1 |
| Lisziewicz, J | 2 |
| Gallo, RC | 3 |
| Bianchi, V | 1 |
| Borella, S | 1 |
| Calderazzo, F | 1 |
| Ferraro, P | 1 |
| Chieco Bianchi, L | 1 |
| Reichard, P | 1 |
| Lafeuillade, A | 1 |
| Pellegrino, P | 1 |
| Poggi, C | 1 |
| Profizi, N | 1 |
| Thiebaut, C | 1 |
| Giacca, M | 1 |
| Zanussi, S | 1 |
| Comar, M | 1 |
| Simonelli, C | 1 |
| Vaccher, E | 1 |
| de Paoli, P | 1 |
| Tirelli, U | 1 |
| Malykh, AG | 1 |
| Foli, A | 1 |
| De Antoni, A | 1 |
| Minoli, L | 1 |
| Padrini, D | 1 |
| Degli Antoni, A | 1 |
| Barchi, E | 1 |
| Jessen, H | 1 |
| Wainberg, MA | 1 |
| Gwilt, PR | 1 |
| Tracewell, WG | 1 |
| Yerly, S | 1 |
| Rutschmann, OT | 1 |
| Opravil, M | 1 |
| Marchal, F | 1 |
| Hirschel, B | 1 |
| Perrin, L | 1 |
| Grunke, M | 1 |
| Dechant, C | 1 |
| Löw, P | 1 |
| Rascu, A | 1 |
| Kalden, JR | 1 |
| Harrer, T | 1 |
| Mayhew, CN | 1 |
| Phillips, JD | 1 |
| Greenberg, RN | 1 |
| Birch, NJ | 1 |
| Elford, HL | 1 |
| Gallicchio, VS | 1 |
| Gibbs, MA | 1 |
| Sorensen, SJ | 1 |
| Clotet, B | 1 |
| Ruiz, L | 1 |
| Cabrera, C | 1 |
| Ibáñez, A | 1 |
| Cañadas, MP | 1 |
| Sirera, G | 1 |
| Romeu, J | 1 |
| Vila, J | 1 |
| Paul, W | 1 |
| James, JS | 1 |
| Agosto, M | 1 |
3 reviews available for hydroxyurea and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocyte | 2011 |
Pharmacokinetics and pharmacodynamics of hydroxyurea.
Topics: Acquired Immunodeficiency Syndrome; Anemia, Sickle Cell; Anti-HIV Agents; Antineoplastic Agents; Ant | 1998 |
Hydroxyurea in the treatment of HIV-1.
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; HIV-1; Humans; Hydroxyurea; Nucleic Acid Synthes | 2000 |
6 trials available for hydroxyurea and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Area Under Curve; Biological Availability; Cros | 2010 |
Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; HIV-1; Humans; Hydroxyure | 2005 |
Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; DNA, Viral; Enzyme Inhibitors; Fe | 1996 |
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cells; Didanosine; Dose-R | 1997 |
Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8- | 1999 |
Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Huma | 1999 |
11 other studies available for hydroxyurea and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
When will once (-a day) be enough?
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cy | 2000 |
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; | 2004 |
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Topics: Acquired Immunodeficiency Syndrome; Cell Survival; Didanosine; DNA Replication; DNA, Viral; Dose-Res | 1994 |
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cells, Cultured; Cytidine; Deoxycytidine; Gemc | 1994 |
Hydroxyurea and HIV-1 viraemia.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV In | 1995 |
Hydroxyurea and AIDS: an old drug finds a new application?
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; HIV-1; Humans; Hydroxyurea | 1995 |
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Anti-HIV Agents; Benzamidines; Cells, Cultured; | 1999 |
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug T | 1996 |
Basic science and clinical trials: interview with William Paul, director of the Office of AIDS Research. Interview by John S James.
Topics: Acquired Immunodeficiency Syndrome; Animals; Clinical Trials as Topic; Disease Models, Animal; Human | 1995 |
Hydroxyrea and ddI: French study published.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy | 1995 |
Moving forward: a treatment overview from the 12th World AIDS Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; | 1998 |